

Product Data Sheet

Product Name: Isavuconazole-d4

Cat. No.: GC47460

Chemical Properties

Cas. No. 1346598-58-0

SMILES FC(C=CC(F)=C1)=C1[C@](CN2N=CN=C2)(O)[C@@H](C)C3=NC(C4=C([2H])C([2H])=C(C#N)C([2H])=C4[2H])=CS3

Formula C₂₂H₁₃D₄F₂N₅OS

M.Wt 441.5


Solubility Acetonitrile: soluble

Storage Store at -20°C

General For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the tips ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Evaluation sample solution : ship with blue ice All other available size: ship with RT, or Condition blue ice upon request.

Structure



Background

Isavuconazole-d₄ is intended for use as an internal standard for the quantification of isavuconazole by GC- or LC-MS. Isavuconazole is a broad-spectrum triazole antifungal agent.¹ It inhibits the growth of clinical isolates of *A. fumigatus*, *A. terreus*, *A. flavus*, and *A. lentulus* (MIC₉₀s = 0.39, 0.39, 2, and 0.25 mg/L, respectively) as well as *C. albicans*, *C. krusei*, and *C. parapsilosis* (MIC₅₀s = 0.03, 0.06, and 0.03 mg/L, respectively).^{1,2,3,4} Isavuconazole also inhibits the growth of several other fungal species, including clinical isolates of *C. neoformans* and *C. gattii* (MIC₉₀s = 0.032 and 0.125 mg/L, respectively).^{1,3} Formulations containing isavuconazole have been used in the treatment of invasive aspergillosis and mucormycosis.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

1. Yamazaki, T., Inagaki, Y., Fujii, T., et al. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan. *Int. J. Antimicrob. Agents* 36(4):324-331 (2010)

2. Rudramurthy, S.M., Chakrabarti, A., Geertsen, E., et al. In vitro activity of isavuconazole against 208 *Aspergillus flavus* isolates in comparison with 7 other antifungal agents: Assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. *Diagn. Microbiol. Infect. Dis.* 71(4):370-377 (2011)

3. Datta, K., Rhee, P., Byrnes, E., III, et al. Isavuconazole activity against *Aspergillus lentulus*, *Neosartorya udagawae*, and *Cryptococcus gattii*, emerging fungal pathogens with reduced azole susceptibility. *J. Clin. Microbiol.* 51(9):3090-3093 (2013)

4. Astvad, K.M.T., Hare, R.K., and Arendrup, M.C. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical *Candida* and *Aspergillus* isolates. *Clin. Microbiol. Infect.* 23(11):882-887 (2017)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA